^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PM1003

    i
    Other names: PM1003, PM 1003, PM-1003
    Company:
    BioNTech
    Drug class:
    PD-L1 inhibitor, CD137 agonist
    Related drugs:
    over2years
    Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=285, Recruiting, Biotheus Inc.
    New P1/2 trial • Metastases
    |
    PM1003